Tuis038290 • KOSDAQ
add
Macrogen Inc
Vorige sluiting
₩15 360,00
Dagwisseling
₩15 260,00 - ₩15 530,00
Jaarwisseling
₩14 700,00 - ₩24 600,00
Markkapitalisasie
167,61 mjd KRW
Gemiddelde volume
11,44 k
P/V-verhouding
-
Dividend-opbrengs
1,94%
Primêre beurs
KOSDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (KRW) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 40,96 mjd | 29,46% |
Bedryfskoste | 16,98 mjd | 24,32% |
Netto inkomste | -2,22 mjd | -3,18% |
Netto winsgrens | -5,42 | 20,29% |
Wins per aandeel | — | — |
EBITDA | -346,40 m | -122,27% |
Effektiewe belastingkoers | 1,39% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (KRW) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 43,70 mjd | 99,38% |
Totale bates | 332,81 mjd | 26,75% |
Totale aanspreeklikheid | 161,36 mjd | 50,90% |
Totale ekwiteit | 171,45 mjd | — |
Uitstaande aandele | 10,84 m | — |
Prys om te bespreek | 1,07 | — |
Opbrengs op bates | -2,30% | — |
Opbrengs op kapitaal | -3,02% | — |
Kontantvloei
Netto kontantverandering
| (KRW) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -2,22 mjd | -3,18% |
Kontant van bedrywe | 362,70 m | 109,97% |
Kontant van beleggings | -8,90 mjd | -43,15% |
Kontant van finansiering | 5,06 mjd | 14,81% |
Netto kontantverandering | -3,06 mjd | 33,91% |
Beskikbare kontantvloei | -2,12 mjd | 88,42% |
Meer oor
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Gestig
05 Jun. 1997
Webwerf
Werknemers
500
